Yale University

Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions.

TitleImpact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions.
Publication TypeJournal Article
Year of Publication2012
AuthorsPowell, Suzanne E., Susan Hariri, Martin Steinau, Heidi M. Bauer, Nancy M. Bennett, Karen C. Bloch, Linda M. Niccolai, Sean Schafer, Elizabeth R. Unger, and Lauri E. Markowitz
JournalVaccine
Volume31
Issue1
Pagination109-13
Date Published2012 Dec 17
ISSN1873-2518
KeywordsAdolescent, Adult, Cervical Intraepithelial Neoplasia, Female, Human papillomavirus 16, Human papillomavirus 18, Humans, Papillomaviridae, Papillomavirus Vaccines, Uterine Cervical Diseases, Young Adult
AbstractVaccination against human papillomavirus (HPV) types 16 and 18 is recommended for girls aged 11 or 12 years with catch-up vaccination through age 26 in the U.S. Cervical intraepithelial neoplasia (CIN) grade 2 or 3 and adenocarcinoma in situ (CIN2+) are used to monitor HPV vaccine impact on cervical disease. This report describes vaccination status in women diagnosed with CIN2+ and examines HPV vaccine impact on HPV 16/18-related CIN2+.
DOI10.1002/cncr.28038
Alternate JournalVaccine

External Links